Neuropeptides as positive or negative neuronal growth regulatory factors: Effects of ACTH and Leu-enkephalin on cultured serotonergic neurons

M. I. Davila-Garcia, Efrain Azmitia

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Abstract

In summary, we have presented evidence that neuropeptides can function as either positive or negative growth regulatory factors during development. The ACTH family of peptides appear to act predominantly as a positive growth regulatory factor - enhancing neurite outgrowth, cell survival, biochemical maturation and behavioral expression. These effects of ACTH are most pronounced prior to the time the afferent cell has reached its target. Thus, ACTH may act as a low level general neurotrophic growth regulatory factor. The opioids have the opposite effect. These neuropeptides inhibit neurite extension, cell survival, and biochemical maturation. The effects of these negative growth regulatory factors are observed when the afferents have reached their targets. The action of the opioids is thought to occur through specific receptors and known second messenger systems. Thus, CNS neuropeptide levels can have important actions in regulating the development of a variety of CNS systems, and permanently influencing the structure and function of the brain.

Original languageEnglish (US)
Title of host publicationAdvances in Experimental Medicine and Biology
Pages75-92
Number of pages18
Volume265
StatePublished - 1990

Fingerprint

Leucine Enkephalin
Serotonergic Neurons
Neuropeptides
Adrenocorticotropic Hormone
Neurons
Intercellular Signaling Peptides and Proteins
Opioid Analgesics
Cell Survival
Cells
Second Messenger Systems
Neurites
Brain
Peptides

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Neuropeptides as positive or negative neuronal growth regulatory factors : Effects of ACTH and Leu-enkephalin on cultured serotonergic neurons. / Davila-Garcia, M. I.; Azmitia, Efrain.

Advances in Experimental Medicine and Biology. Vol. 265 1990. p. 75-92.

Research output: Chapter in Book/Report/Conference proceedingConference contribution

@inproceedings{c21ab8d87caf4c47a16f43aa73d51f06,
title = "Neuropeptides as positive or negative neuronal growth regulatory factors: Effects of ACTH and Leu-enkephalin on cultured serotonergic neurons",
abstract = "In summary, we have presented evidence that neuropeptides can function as either positive or negative growth regulatory factors during development. The ACTH family of peptides appear to act predominantly as a positive growth regulatory factor - enhancing neurite outgrowth, cell survival, biochemical maturation and behavioral expression. These effects of ACTH are most pronounced prior to the time the afferent cell has reached its target. Thus, ACTH may act as a low level general neurotrophic growth regulatory factor. The opioids have the opposite effect. These neuropeptides inhibit neurite extension, cell survival, and biochemical maturation. The effects of these negative growth regulatory factors are observed when the afferents have reached their targets. The action of the opioids is thought to occur through specific receptors and known second messenger systems. Thus, CNS neuropeptide levels can have important actions in regulating the development of a variety of CNS systems, and permanently influencing the structure and function of the brain.",
author = "Davila-Garcia, {M. I.} and Efrain Azmitia",
year = "1990",
language = "English (US)",
volume = "265",
pages = "75--92",
booktitle = "Advances in Experimental Medicine and Biology",

}

TY - GEN

T1 - Neuropeptides as positive or negative neuronal growth regulatory factors

T2 - Effects of ACTH and Leu-enkephalin on cultured serotonergic neurons

AU - Davila-Garcia, M. I.

AU - Azmitia, Efrain

PY - 1990

Y1 - 1990

N2 - In summary, we have presented evidence that neuropeptides can function as either positive or negative growth regulatory factors during development. The ACTH family of peptides appear to act predominantly as a positive growth regulatory factor - enhancing neurite outgrowth, cell survival, biochemical maturation and behavioral expression. These effects of ACTH are most pronounced prior to the time the afferent cell has reached its target. Thus, ACTH may act as a low level general neurotrophic growth regulatory factor. The opioids have the opposite effect. These neuropeptides inhibit neurite extension, cell survival, and biochemical maturation. The effects of these negative growth regulatory factors are observed when the afferents have reached their targets. The action of the opioids is thought to occur through specific receptors and known second messenger systems. Thus, CNS neuropeptide levels can have important actions in regulating the development of a variety of CNS systems, and permanently influencing the structure and function of the brain.

AB - In summary, we have presented evidence that neuropeptides can function as either positive or negative growth regulatory factors during development. The ACTH family of peptides appear to act predominantly as a positive growth regulatory factor - enhancing neurite outgrowth, cell survival, biochemical maturation and behavioral expression. These effects of ACTH are most pronounced prior to the time the afferent cell has reached its target. Thus, ACTH may act as a low level general neurotrophic growth regulatory factor. The opioids have the opposite effect. These neuropeptides inhibit neurite extension, cell survival, and biochemical maturation. The effects of these negative growth regulatory factors are observed when the afferents have reached their targets. The action of the opioids is thought to occur through specific receptors and known second messenger systems. Thus, CNS neuropeptide levels can have important actions in regulating the development of a variety of CNS systems, and permanently influencing the structure and function of the brain.

UR - http://www.scopus.com/inward/record.url?scp=0025340068&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025340068&partnerID=8YFLogxK

M3 - Conference contribution

C2 - 2165733

AN - SCOPUS:0025340068

VL - 265

SP - 75

EP - 92

BT - Advances in Experimental Medicine and Biology

ER -